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The accumulation of amyloid-beta (Ab) and tau aggregates is a pathological hallmark of Alzheimer’s
disease. Both polypeptides form ﬁbrillar deposits, but several lines of evidence indicate that Ab and
tau form toxic oligomeric aggregation intermediates. Depleting such structures could thus be a
powerful therapeutic strategy. We generated a fragment of tau (His-K18DK280) that forms stable,
toxic, oligomeric tau aggregates in vitro. We show that ()-epigallocatechin gallate (EGCG), a green
tea polyphenol that was previously found to reduce Ab aggregation, inhibits the aggregation of tau
K18DK280 into toxic oligomers at ten- to hundred-fold substoichiometric concentrations, thereby
rescuing toxicity in neuronal model cells.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction domains of the microtubule-binding domain of the longest humanA variety of peptides and proteins are known to assemble into
highly ordered aggregate structures with a cross-beta sheet
structure, termed amyloid. The brains of patients suffering from
Alzheimer’s disease (AD) exhibit two types of aggregated protein
deposits: extracellular plaques mainly composed of amyloid-beta
(Ab) peptide and intracellular neuroﬁbrillary tangles composed of
the hyperphosphorylated protein tau, in which the microtubule-
binding repeat domain adopts a cross-beta structure [1–4]. Tau
exists in multiple splicing variants and is a highly hydrophilic
and thus soluble protein with little propensity to aggregate [5].
The K18DK280 tau protein fragment spans the four repeatisoform tau40; the deletion of lysine 280 has been described in
FTDP-17 [6] (Fig. 1A). Filaments of wild-type (wt) tau only form
in vitro in the presence of polyanions such as heparin [7,8], how-
ever K18DK280 aggregates into b-sheet rich structures without
heparin [9].
Therapeutic efforts into slowing or reversing the progression of
neurodegenerative diseases have concentrated on clearing insolu-
ble protein aggregates or inhibiting the aggregation of amyloido-
genic proteins. In recent years, new therapeutic strategies have
emerged, which include the stabilization of mature ﬁbrils to
deplete toxic oligomers or the redirection of the aggregation cas-
cade to increase the formation of non-toxic, off-pathway aggre-
gates [10].
Since two types of ﬁbrillar aggregates are formed from Ab and
tau in AD, small molecules targeting both polypeptides could be
a valuable therapeutic strategy. Inhibitors of heparin-induced tau
paired helical ﬁlament formation were found in the classes of
anthraquinones, polyphenols, porphyrins and phenothiazines
[11,12]. The green tea polyphenol ()-epigallocatechin gallate
(EGCG) interferes with aggregation of numerous amyloidogenic
proteins and small polypeptides and ameliorates their detrimental
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tured, off-pathway oligomers from Ab, a-synuclein and IAPP
in vitro [19,20]. Despite challenges in its variable oral bioavailabil-
ity, short pharmacokinetic half-life, and limited partitioning across
the blood–brain barrier, this may make it a promising model drug
for AD [21,22]. However, the effect of EGCG on tau aggregation has
not yet been characterized. Here, we developed a cell-free aggrega-
tion assay using the tau fragment His-K18DK280 to probe the
effect of EGCG under physiological conditions in the absence of
heparin. We demonstrate that EGCG prevents the formation of b-
sheet rich aggregates at substoichiometric concentrations and
reduces their toxicity in cell-based assays, suggesting a speciﬁc
interaction of EGCG with a crucial early aggregation intermediate.
2. Materials and methods
2.1. Protein expression and puriﬁcation
The construct encoding the tau fragment K18 (K18DK280,
Fig. 1A), comprising the mutant four-repeat microtubule-binding
domain, was kindly provided by M. Holzer. Expression clones for
K18DK280 with an N-terminal His6-tag were generated using the
Gateway technology (Life Technologies). AttB sites were added
to the construct by PCR (forward primer: 50-GGGGACAAGTTTGTA
CAAAAAAGCAGGCTGGatgcagacagcccccgtgcccatgc-30; reverse pri-
mer: 50-GGGGACCACTTTGTACAAGAAAGCTGGGTGTCATTCAATCTT
TTTATTTCCTCC-30). pDONR221 and pDESTco were chosen as entry
and expression vectors, respectively. Ni–NTA matrix columns were
used for puriﬁcation of recombinant protein (QIAGEN). Columns
were washed with native wash buffer or with wash buffers of
decreasing urea concentrations, and the His-tagged protein was
eluted under native conditions following the manufacturer’s spec-
iﬁcations (QIAGEN).
The protein was subjected to reversed-phase puriﬁcation using
Poros 50 R1 resin (Applied Biosciences), washed using 0.1% triﬂuo-
roacetic acid (TFA), and eluted with 60% acetonitrile/0.1% TFA,
lyophilized and the aliquots stored at 20 C. Protein concentra-
tion was determined by OD280 using an extinction coefﬁcient of
8480 M1cm1.
2.2. Protein aggregation
Lyophilized His-K18DK280 protein was reconstituted in PBS
and sonicated at 4 C for 5 min. The protein solution was cleared
by centrifugation at 200000g and 4 C for 20 min. His-
K18DK280was incubated at 37 C in 96-well plates at 12.5 lM,
with 5 mM dithiothreitol (DTT) added daily to prevent formation
of intramolecular disulﬁde bonds. EGCG (Sigma Aldrich) solutions
were freshly prepared with ultrapure H2O.
2.3. Thioﬂavin T assay
To measure aggregation formation, 20 lM Thioﬂavin T (ThT)
was added to each reaction and ﬂuorescence measured in tripli-
cates in black non-binding 96-well plates with clear, ﬂat bottoms
(#3651, Corning) using a microplate reader (Inﬁnite M200, Tecan),
at excitation and emission wavelengths of 440 and 485 nm, respec-
tively. Results were calculated as means ± S.D.
2.4. SDS–PAGE and dot blot assays
Protein samples were either denatured by boiling at 95 C for
10 min with 2% SDS + 50 mM DTT for denaturing SDS–PAGE and
denaturing dot blots or diluted with an equal volume of H2O for
non-denaturing dot blots. 20 ll were applied to nitrocellulosemembranes. Membranes were blocked for 1 h in 3% non-fat milk
and incubated overnight with the following primary antibodies
at 4 C: polyclonal anti-tau A0024 (aa 243-441, DAKO; 1:2000),
anti-amyloid oligomer A11 (1:2000, Life Technologies). Proteins
were visualized by chemiluminescence (Chemicon) or the Atto-
Phos reagent (Promega). NBT staining of nitrocellulose membranes
was performed as previously described [19,23].
2.5. Centrifugal sedimentation
Samples were collected every 24 h and subjected to ultracentri-
fugation for 20 min at 200000g (70000 rpm) and 4 C in a TL-100
centrifuge and TLA120.2 rotor (Beckman). Pellets were resuspended
in PBS. Unfractionated samples, supernatants and resuspended pel-
lets were boiled in SDS sample buffer, resolved by SDS–PAGE and
visualized by silver staining as previously described [24].
2.6. Atomic force microscopy (AFM)
20 ll of His-K18DK280 samples were pipetted onto freshly
cleaved mica ﬁxed onto a glass slide and incubated for 10 min at
room temperature, washed 3 with H2O, and dried overnight.
Samples were analyzed using the Nanowizard AFM (JPK, Berlin)
in intermittent contact mode.
2.7. Tryptophan ﬂuorescence spectroscopy
Protein solutions were diluted 1:10 in PBS. Fluorescence emis-
sion was measured at 280 nm absorption wavelength using a ﬂuo-
rescence spectrometer (LS 50, Perkin Elmer).
2.8. Cell viability assay
PC-12 cells (American Type Culture Collection) were grown in
DMEM F12-K medium supplemented with 14.5% horse serum, 4%
fetal calf serum, 100 U/ml penicillin and 100 lg/ml streptomycin
at 37 C with 5% CO2 in a humidiﬁed environment. Prior to viability
assays, DTT was removed from K18DK280 aggregate reactions by
buffer exchange using a 10kDa centrifugal ﬁlter (Amicon) or by
pelleting aggregates by ultracentrifugation (200000g, 20 min),
washing and resuspending in PBS. Cell viability was measured
using the MTT assay as previously described [19]. Student’s t-test
was used to calculate P values.3. Results
3.1. EGCG substoichiometrically prevents the formation of SDS-stable
tau oligomers
First, we assessed the aggregation of tau K18DK280 (Fig. 1A) in
the absence or presence of EGCG (Fig. 1B) by measuring Thioﬂavin
T (ThT) ﬂuorescence emission at 485 nm under reducing
conditions (Fig. 1C). ThT increases ﬂuorescence on binding to
b-sheet rich amyloid-like structures [25]. In the absence of EGCG,
ThT ﬂuorescence increased after an initial lag phase of ca
24–30 h. In contrast, incubation of K18DK280 with a substoichio-
metric concentration of EGCG (0.01 tau protein) elongated the
lag phase. At higher concentrations of EGCG (0.1, 1 and 5),
no increase in ThT ﬂuorescence was observed (Fig. 1C), indicating
that EGCG blocks the formation of amyloid-like, b-sheet rich tau
aggregates. In contrast, EGCG did not prevent the rapid formation
of b-sheet rich K18DK280 aggregates that were induced by
heparin (Supplementary Figs. S1 and S2A), but changed aggregate
morphology from large ﬁbrillar assemblies into smaller spherical
structures (Supplementary Fig. S2B). Likewise, EGCG reduced ThT
Fig. 1. EGCG prevents the formation of tau oligomers and SDS-stable aggregates at substoichiometric concentrations. (A) Structure of the K18D280 tau fragment comprising
all four repeat domains (T1–4) of the microtubule-binding domain found in the longest human tau isoform tau40 and with a deletion of lysine residue 280. (B) Structure of
()-epigallocatechin gallate (EGCG). (C) Effect of ECGC on tau K18DK280 aggregation (12.5 lM) as assessed by ThT ﬂuorescence assay. Results represent mean ﬂuorescence
signal ± S.D. (n = 3). (D) Effects of EGCG (equimolar concentration) on the formation of SDS-stable, high molecular weight tau aggregates. T = total, unfractionated sample,
S = supernatant, P = pellet. Fractionation by centrifugal sedimentation at 200000g. (E) Analysis of untreated and EGCG-treated (equimolar concentration) K18DK280 by
atomic force microscopy after 0 h, 48 h and 120 h incubation at 37 C. Scale bar = 500 nm. (F) Effects of EGCG on the formation of tau oligomers as assessed by A11 dot blot
analysis.
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reducing (wt tau) and oxidizing conditions (DC tau), but did not
delay aggregation or alter the ﬁbrillar morphology of tau aggre-
gates under these conditions (Supplementary Fig. S3).
We next analyzed the effects of EGCG on tau aggregation by
centrifugal fractionation of samples followed by denaturing SDS–
PAGE and silver staining (Fig. 1D). In the absence of EGCG, we
found a time-dependent increase of tau in the pellet fractions, indi-
cating the formation of insoluble, high molecular weight aggre-
gates (Fig. 1D). In addition, SDS-stable multimers appeared from
48 h onwards. In contrast, incubation of the tau fragment with
equimolar EGCG eliminated the formation of SDS-stable aggregates
(Fig. 1D). Thus, our centrifugation assays conﬁrm that EGCG treat-
ment potently blocks K18DK280 aggregation in vitro.
To visualize K18DK280 aggregate species, we performed atomic
force microscopy (AFM) on samples incubated with or without
equimolar concentrations of EGCG. In the absence of EGCG, weobserved the time-dependent formation of non-ﬁbrillar, oligo-
meric K18DK280 aggregate species (Fig. 1E). In contrast, only a
few small tau aggregate species were observed after incubation
with EGCG.
Finally, we performed dot blot assays with the anti-oligomer
antibody A11 in order to examine whether the spontaneously
formed K18DK280 aggregates are toxic, disease relevant struc-
tures. Previous studies have demonstrated that A11 detects prote-
otoxic, oligomeric aggregate species of Ab, tau and other
polypeptides but not ﬁbrils or monomers [26,27]. In the absence
of EGCG, dot blot analysis revealed strong A11 signals at 72 and
96 h, supporting the results by AFM that predominantly oligomeric
K18DK280 aggregates are spontaneously formed in vitro (Fig. 1E).
Interestingly, at 120 h, the A11 signal decreased, which could be
due to the formation of the larger aggregates that are less
efﬁciently recognized by the antibody. In samples of K18DK280
co-incubated with EGCG, we observed no time-dependent increase
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potentially proteotoxic oligomeric tau species.
Taken together, these data indicate that EGCG is a potent inhib-
itor of K18DK280 aggregation in vitro, which blocks the formation
of insoluble, high-molecular weight, SDS-stable tau oligomers at
substoichiometric concentrations.
3.2. EGCG prevents tau conformational changes and rescues tau
toxicity in vitro
Next, we scrutinized the effect of EGCG on the structure of tau
K18DK280. First, we tested if EGCG bound to the monomer or to
some other tau species. After incubation with EGCG (5 molar
ratio) we performed SDS–PAGE and detected tau by silver staining
and EGCG by electroblotting and subsequent staining with the
redox-sensitive dye nitroblue tetrazolium (NBT), which detects
EGCG-bound polypeptides [19,28]. As before, treatment with EGCG
prevented the formation of SDS-resistant tau dimers, oligomers, or
aggregates (Fig. 2A). However, a second (18kDa) band appeared
after 24 h with slightly lower mobility than the tau monomer
(16kDa). This band reacted weakly with silver staining, but
strongly with the EGCG-sensitive dye NBT. This suggests that the
bulk of the protein exists as a monomer that is not bound to EGCG,
but that a subpopulation of EGCG-bound tau molecules exists.
These molecules are either monomers that have a conformation
that is distinct from the unbound tau monomers, or they are pres-
ent in the form of SDS-labile oligomers.
To further assess the effects of EGCG on K18DK280 misfolding
and aggregation, we performed dot blot assays under native condi-
tions using the anti-tau antibody A0024 (Fig. 2B and C). In the
absence of EGCG, antibody binding decreased from 48 h onwards.
After 96 h of incubation, no tau signal could be detected (Fig. 2B).
In contrast, the protein could be detected with the A0024 antibody
after 96 h or 120 h in samples incubated with EGCG at 1:100 or
1:10 ratios, respectively. Tau was detected in all samples when
re-probed with the same antibody under denaturing conditions
(Fig. 2C), conﬁrming that the loss of antibody binding indicated a
change in secondary and/or tertiary structure during tau aggrega-
tion, which was prevented by EGCG treatment.
We speculated that EGCG might prevent early conformational
changes in the tau fragment K18DK280 that could trigger subse-
quent aggregation. To investigate this hypothesis, we performed
tryptophan ﬂuorescence and circular dichroism spectroscopy
(Fig. 2D and E). In the absence of EGCG, the tryptophan ﬂuores-
cence emission spectrum of monomeric K18DK280 (incubation
time 0 h) showed a maximum emission at approximately
350 nm. After 120 h of incubation, a hypsochromic shift in the
emission spectrum was observed, with maximum emission at
335 nm. This shift in emission was abrogated by co-incubation of
K18DK280 with EGCG, suggesting that EGCG suppresses the con-
formational changes observed in untreated protein samples. Corre-
spondingly, circular dichroism spectra before and after incubation
with EGCG both indicated that the protein was largely unstruc-
tured and did not adopt a b-sheet conformation (Fig. 2E).
Finally, we investigated whether EGCG-treated or -untreated
tau aggregates are toxic to mammalian cells. To this end, we incu-
bated K18DK280 for 144 h in the presence or absence of EGCG and
then ﬁltered K18DK280 aggregate samples using a 10kDa ﬁlter to
remove all small molecules while retaining all tau species. Solu-
tions were then applied to PC-12 cells for 72 h, and cell viability
was measured by MTT reduction (Fig. 2F). Our results showed a
signiﬁcant cellular toxicity of aggregated K18DK280, which was
rescued by co-incubation of the protein with EGCG. To conﬁrm that
tau toxicity and its rescue by EGCG was linked to the aggregation
of tau, we pelleted aggregated tau by ultracentrifugation and
washed the pellet to remove DTT, EGCG, and soluble tau protein(Fig. 2G). We found that the resuspended aggregates were toxic
to PC-12 cells as assessed by the MTT assay, whereas pellets from
EGCG-treated samples were neither toxic nor contained any tau
protein. This conﬁrmed that tau toxicity was linked to its aggrega-
tion and that EGCG prevented the formation of toxic tau
aggregates.4. Discussion
Alzheimer’s disease is characterized by the two aggregated pro-
tein species Ab and tau [1,2]. While much effort has been put into
elucidating the mechanisms of Ab polymerization, and a large body
of evidence exists for a toxic role of Ab oligomers in AD pathology
[29–31], studies investigating the aggregation mechanism of the
microtubule-associated protein tau have been less numerous.
Recently, oligomeric forms of tau isolated from AD brains were
found to be potently toxic [32,33] and have been discussed as
potential targets for therapeutic intervention [34–36]. The aim of
this study was therefore to establish a model for tau oligomeriza-
tion in vitro, and to investigate the effects of the green tea
polyphenol EGCG on tau oligomerization without the help of
polyanions.
EGCG has been implicated in several studies as a drug
candidate that modulates the aggregation of proteins implicated
in neurodegenerative diseases, such as huntingtin, amyloid-beta
and a-synuclein [19,23]. We found that EGCG strongly inhibits
tau aggregation even at highly substoichiometric concentrations,
suggesting that the compound may target an aggregation
intermediate that appears early in the amyloid formation cascade.
However, loss of ThT ﬂuorescence by itself is not a reliable marker
for a loss of amyloid-like structures [37]. Several hypotheses could
explain the effect of EGCG on ThT ﬂuorescence: (1) EGCG binds to
K18DK280 without altering aggregation, but displaces ThT; (2) in
the presence of EGCG, K18DK280 aggregation is redirected into a
distinct aggregate species that has no afﬁnity for ThT; (3) EGCG
prevents the polymerization of K18DK280, so that the protein lar-
gely remains in its natively unfolded monomeric form. We will
discuss these possible mechanisms in the following paragraphs.
Sedimentation assays indicated that EGCG indeed inhibits poly-
merization of tau into high molecular weight aggregates; however,
they do not exclude the formation of SDS-labile, low-molecular
aggregates in the presence of EGCG. We performed atomic force
microscopy to investigate whether such aggregates might be
formed in the presence of EGCG. Spherical and amorphous aggre-
gates of K18DK280 were detectable from 48 h onwards in the
absence of EGCG, but not in its presence, indicating that if such
aggregates form in the presence of EGCG, they are rare. The hypso-
chromic shift in tryptophan ﬂuorescence of tau oligomers and the
masking of antibody binding epitopes compared to monomeric
protein indicated a structural change during aggregation that
was prevented by EGCG. Dot blot analysis using anti-oligomer
antibody A11 and circular dichroism spectroscopy further
corroborated that EGCG prevents the formation of b-sheet-rich
oligomeric tau species.
In summary, these data strongly support the hypothesis that
EGCG prevents the formation of toxic tau oligomers and keeps
the bulk of the tau fragment in a monomeric, unfolded state. In
contrast, previous data on Ab, a-synuclein, and IAPP indicated that
EGCG induces a speciﬁc conformational change and redirects these
polypeptides into off-pathway aggregation [14,19]. Since EGCG
inhibited tau aggregation at highly substoichiometric concentra-
tions, stable, quantitative binding to the tau monomer cannot
explain its effect. Rather, we conclude that EGCG binds to a rare
partially misfolded monomeric or oligomeric tau species. Quinoid
substances such as EGCG can covalently bind proteins [28]. While
Fig. 2. EGCG prevents tau conformational changes and rescues tau toxicity. (A) EGCG binding to K18DK280 visualized by NBT staining (right) compared to silver stained
protein (left). Asterisk indicates monomer band, arrowhead band stained by NBT. (B) Dot blot analysis of non-denatured K18DK280 protein incubated in the absence (0) or
presence of substoichiometric (0.01 and 0.1) concentrations of EGCG for 0–120 h. (C) Dot blot analysis of denatured samples of K18DK280 incubated under the same
conditions. (D) Tryptophan ﬂuorescence spectra of K18DK280 (12.5 lM) incubated for 0 h or 120 h in the absence or presence of equimolar concentrations of EGCG
(tryptophan absorption wavelength 280 nm). (E) Circular dichroism spectra of K18DK280 (12.5 lM) incubated with EGCG. (F and G) Assessment of tau K18DK280 toxicity
using the MTT metabolic assay. PC-12 cells were incubated with protein incubated in the absence or presence of EGCG for 144 h. (F) Protein samples were ﬁltered using a
10kDa size exclusion ﬁlter. (G) Samples were pelleted by ultracentrifugation, washed and resuspended in PBS. Results represent means ± S.D. (n = 3). ⁄P < 0.05, ⁄⁄P < 0.01,
⁄⁄⁄P < 0.001 (Student’s t-test).
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debated [20,37], the appearance of a distinct population of EGCG-
bound tau molecules in SDS gels (Fig. 2A) indicates tight, and pos-
sibly irreversible, binding of EGCG to a subpopulation of the tau
protein. This suggests a mechanism in which EGCG binds to a rare
aggregation nucleus and converts it into an inactive conformation,
thus removing its seeding activity.The apparent difference in mechanism of EGCG between
K18DK280 polymerization on one hand and Ab, IAPP and a-synuc-
lein polymerization on the other hand, would then result from the
rare occurrence of nucleus formation in tau, when compared to
nucleus formation of other polypeptides [19,20] (Fig. 3). Corre-
spondingly, the effect of EGCG on heparin induced tau aggregation
more resembled its effect on Ab. Here, the lag phase was very short
Fig. 3. Working model for the effects of ()-epigallocatechin gallate on the
aggregation of tau. In this model, EGCG preferentially binds to a misfolded
monomer or a rare transient nucleus (triangle), not to the unfolded monomer
(circle). Binding of EGCG to the misfolded monomer or nucleus either catalytically
converts it back to its unfolded monomeric form (dashed arrow (1)), or converts it
to an inactive conformation and removes it from the aggregation cascade (dashed
arrow (2)), thus inhibiting subsequent aggregation steps.
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Consequently, EGCG had little effect on aggregation kinetics even
though it did change the structure of heparin-induced K18DK280
aggregates.
Alternatively, EGCG could transiently bind rare oligomers and
catalytically return tau to its unfolded monomeric state, acting as
a chemical chaperone [38,39]. Chemical chaperones have been
shown to both stabilize the native conformation of amyloidogenic
proteins and to destabilize partially folded states [39–41]. The
presence of tightly bound EGCG-tau complexes and the absence
of kinetic inhibition in heparin–induced aggregation both argue
against such a mechanism. However, the methods used in our
study are not sensitive to conformational changes in small subpop-
ulations of the tau protein, so more reﬁned experiments would be
needed to conclusively rule out a catalytic mechanism.
In conclusion, our study indicates that EGCG is a potent inhibi-
tor of tau aggregation and toxicity. Its effect on K18DK280 poly-
merization is distinct from its effects on Ab and a-synuclein
aggregation. Its dual inhibition of Ab and tau aggregation into b-
sheet rich, toxic structures, might be of synergistic beneﬁt for the
treatment of AD.
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